Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Interest & Investment Income (2020 - 2026)

C4 Therapeutics has reported Interest & Investment Income over the past 7 years, most recently at $2.7 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 6.54% year-over-year to $2.7 million; the TTM value through Mar 2026 reached $10.2 million, down 24.23%, while the annual FY2025 figure was $10.3 million, 28.28% down from the prior year.
  • Interest & Investment Income for Q1 2026 was $2.7 million at C4 Therapeutics, down from $2.8 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $3.9 million in Q1 2024 and troughed at $276000.0 in Q1 2022.
  • A 5-year average of $2.4 million and a median of $2.6 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 1156.62% in 2022 and later tumbled 37.23% in 2025.
  • Year by year, Interest & Investment Income stood at $1.7 million in 2022, then soared by 72.62% to $2.9 million in 2023, then grew by 10.75% to $3.3 million in 2024, then fell by 14.91% to $2.8 million in 2025, then decreased by 4.46% to $2.7 million in 2026.
  • Business Quant data shows Interest & Investment Income for CCCC at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.2 million in Q3 2025.